Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma
Status:
Not yet recruiting
Trial end date:
2028-08-01
Target enrollment:
Participant gender:
Summary
This study aimed to evaluate the efficacy of a novel regimen consisting of polatuzumab
vedotin in combination with rituximab, gemcitabine, dexamethasone, and cisplatin (PV-RGDP)
for the treatment of diffuse large B-cell lymphoma that either came back or did not improve
after the treatments (rrDLBCL).
This combination has not been approved by the Food and Drug Administration (FDA) for the
treatment of rrDLBCL. Salvage therapy (treatment after standard treatment failed) needs to be
improved. Rituximab, gemcitabine, dexamethasone, and cisplatin combination is a standard
therapy for rrDLBCL and polatuzumab vedotin (PV) is a novel antibody-drug conjugate targeting
CD79b. PV has shown efficacy in the setting of rrDLBCL and can improve the response rates of
standard salvage therapy.
This study will focus on subjects in the first relapse (one prior regimen) and will include
both subjects who are transplant eligible and those who are transplant ineligible.